Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

Click to increase image sizeClick to decrease image size

Acknowledgments

We thank SignalRx Pharmaceutical, Inc. for providing SRX3305 and SRX3333 and The Ohio State University Leukemia Tissue Bank staff for primary patient sample procurement services that was supported by the National Cancer Institute grant P30 CA016058. We also thank the Department of Pharmacology and Experimental Neuroscience Elutriation Core at the University of Nebraska Medical Center for the isolation of healthy donor PBLs used in this study. We acknowledge Jinxu Liu for initial inhibitor testing in malignant B-cells lines.

Authors contribution

A.L.S., D.P., R.M.R., and A.P.E. performed the experiments and together with D.L.D., T.G.K., and D.E. analyzed the data. A.L.S., D.P. and D.E. wrote the initial manuscript draft. D.L.D., T.G.K., and D.E. supervised the study. T.G.K. and D.E. obtained funding to support the work. All authors have read and approved the final manuscript.

Disclosure statement

D.L.D. has an equity interest in SignalRx Pharmaceuticals, Inc., which has patent applications pending related to the multi-target inhibitors SRX3305 and SRX3333. All other authors declare no conflict of interest.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

This work was supported in part by institutional startup funds from the Fred and Pamela Buffett Cancer Center of the University of Nebraska Medical Center (UNMC) to D.E. and National Institutes of Health (NIH) grants CA252707 and HL151334 to T.G.K. A.L.S. was supported by a graduate student fellowship from UNMC, R.M.R was supported by an Eppley Institute Summer Undergraduate Research Program (SURP) at UNMC, and A.P.E. was supported by a NIH T32 training grant (CA009476).